Novo Nordisk AS Earnings - Q3 2026 Analysis & Highlights
Byline: Novo Nordisk reported a return to adjusted sales growth in Q3 2026, with growth in both operating units and renewed patient gains; management highlighted GLP-1 demand, product launches and pipeline progress, and raised its 2026 outlook.
Key financial results
Adjusted sales increased 4% to DKK 79.2 billion in Q3 2026, driven by GLP-1 volume growth in the US and International Operations, primarily in obesity.
Adjusted operating profit increased 27%, supported by GLP-1 sales growth and a favorable comparison with Q3 2025, when approximately DKK 9 billion of transformation costs were recognized; Q3 2026 also included around DKK 3.5 billion of one-time costs in other operating expenses and R&D.
Management reported DKK 32 billion in adjusted operating profit and more than DKK 28 billion in free cash flow for the quarter.
No EPS, gross-margin or operating-margin figures were provided in the cited call remarks.
Business segment results
US Operations grew 1% and International Operations (IO) grew 8% in Q3; within IO, EUCAN grew 18%.
IO’s total GLP-1 sales increased 8%, with obesity sales up 24%; EUCAN was the principal regional growth contributor, while lower realized prices after semaglutide loss of exclusivity weighed on Canada.
In the US, Wegovy pill volumes grew about 20% sequentially versus Q2 and injectable Wegovy volumes grew about 10%; management said Bridge Program volume contributed substantially to the pill’s quarterly increase.
Novo said the Wegovy franchise held more than 50% of US new-to-brand prescriptions, while the Wegovy pill captured around 80% of NBRx and had generated more than 8 million cumulative US prescriptions since launch.
The Ozempic pill’s weekly new-to-brand prescriptions had more than doubled since launch, and more than 60% of its new-to-brand prescriptions were from people new to GLP-1 treatment.
Capital allocation
Management said it was directing targeted investment to current and future growth opportunities in R&D and commercial activities, partly funded by transformation-program savings and further optimization initiatives.
The call did not provide specific amounts or plans for dividends, share repurchases, debt repayment or capital expenditures.
Industry trends and dynamics
Novo said it was reaching around 48 million people with diabetes and obesity treatments, 2 million more than a year earlier; it reported treating 5.6 million people for obesity, nearly twice the number from 12 months earlier.
Patient volumes improved: Novo added 1.2 million patients in Q2 and 1.3 million in Q3; obesity added 0.8 million and 0.7 million, respectively, while diabetes added 1 million across the two quarters after a decline in Q1.
In the US, the broader anti-obesity medicine category was relatively flat from May to October excluding Bridge, with management citing seasonality; it expected consumer activation around wellness and New Year’s resolutions to support demand later in the year and early the next year.
Management said payer concern increasingly centered on treatment volume and the resulting cost trend, even as net prices decline and evidence of long-term medical-cost offsets exists.
Competitive landscape
Novo reported a 54% GLP-1 volume share in IO and said it continued to lead the oral obesity segment, with around 90% market share in the UK and around 80% in the UAE in recent weeks.
In the US, Wegovy pill continued to capture around 80% of NBRx; management also described the Wegovy franchise as leading new-to-brand prescriptions with more than 50% market share.
Novo said the UK Wegovy pill was selling around 60,000 packs weekly, compared with approximately 65,000 weekly at Capital Markets Day, and reported that its pill launch was adding to overall market share rather than cannibalizing injectable sales.
Management said Wegovy high dose represented about 5% of total US Wegovy prescriptions, with around 80% of high-dose prescriptions being titrations from 2.4 mg; it viewed these prescriptions as patients who otherwise might have left the Wegovy franchise.
Novo cited competition in reimbursed IO markets and a competitor launch in the UK oral obesity market; it also noted that tirzepatide was the comparator in a CagriSema diabetes trial.
In the CagriSema head-to-head trial, the 1 mg dose of each component delivered 12.4% weight loss versus 9.1% for tirzepatide 5 mg, with HbA1c reduction of around 1.7% described as noninferior.
Macroeconomic environment
US net-price dynamics remained pressured: management described annual Ozempic price erosion of 10%–15% as a reasonable expectation and said Wegovy price erosion had been 30%–35% in the quarter, with that trend or somewhat better expected to continue.
Novo said lower realized US prices linked to market-access investments and the MFN agreement were reflected in its outlook; it also said US list prices would decrease on January 1, 2027.
Management cited China’s existing headwind and a further loss of exclusivity there next year; it also flagged loss-of-exclusivity effects in IO and a less favorable gross-to-net comparison as factors for 2027.
In discussing US access, management said family insurance premiums had risen 28% over five years and that healthcare costs were a concern for both political parties; it said political support could affect continuation of Medicare Bridge coverage beyond its planned end at the end of 2027.
Growth opportunities and strategies
Novo’s 2030 ambition is to deliver mid-single-digit compounded annual sales growth from 2026 to 2030, supported by pipeline diversification, sustainable growth and attractive shareholder returns.
Management described Wegovy pill and high-dose Wegovy as supporting broader patient reach; the IO pill rollout had reached seven markets, with availability expected in more than 20 markets by the first half of 2027.
Novo said manufacturing output and regulatory work enabled it to accelerate the IO pill rollout; it expected 20 markets by the end of the first half of 2027, earlier than previously planned.
The company advanced oral amycretin into Phase 3, with the AMAZE 9 trial readout expected in 2028; it also cited upcoming obesity readouts for Amylin 355 and two tri-agonists, and anticipated Phase 3 initiation for high-dose cagrilintide.
Novo said it submitted US MASH data for oral semaglutide and anticipated a US decision in the first half of 2027.
Management planned a global 2027 rollout of Frehemgo, subject to approval, and said it was preparing to launch CagriSema as quickly as possible after approval.
Novo said it planned to initiate Phase 3 trials in neuropathic pain across its portfolio during 2027, following encouraging CagriSema Phase 2 results.
Financial Guidance and Outlook
Novo raised its 2026 guidance to adjusted sales growth of -2% to +2% and adjusted operating-profit growth of -2% to +2%, both at constant exchange rates.
The revised sales outlook reflected higher expectations for GLP-1 product sales, IO growth and continued volume penetration, alongside expected sales decline in US Operations, lower realized US prices and assumptions for Wegovy pill uptake.
The company increased its free-cash-flow outlook to DKK 60 billion–DKK 70 billion for 2026.
Management did not provide 2027 guidance, but identified potential supports: continued Wegovy pill uptake in the US and IO, annualization of the US Bridge Program and planned CagriSema and Frehemgo launches.
Management identified potential 2027 headwinds including IO loss-of-exclusivity effects, continued China pressure and loss of exclusivity there, and the possibility that favorable 2026 gross-to-net effects would not recur to the same degree.
Leadership
Novo announced that CFO Karsten Munk Knudsen would leave after 27 years with the company and remain through year-end to support the transition; Luigi La Corte, then CFO of Galderma, was named incoming CFO.
